| What it is | A combination of mocertatug rezetecan, an investigational B7-H4-targeted antibody-drug conjugate, and dostarlimab, an immune checkpoint inhibitor, administered by intravenous infusion for advanced or recurrent endometrial cancer. | A treatment approach using mocertatug rezetecan, with or without bevacizumab, given intravenously for advanced epithelial ovarian, fallopian tube, or peritoneal cancer. | Systemic anticancer therapies recommended by clinical guidelines for recurrent or treatment-resistant endometrial and epithelial ovarian cancers, including combination chemotherapy and, where indicated, targeted therapies such as bevacizumab or immune checkpoint inhibitors. |
|---|
| Role in the trial | Investigational therapy tested for safety, tolerability, and antitumor activity in eligible women with advanced or recurrent endometrial cancer, as part of Module 1 of the BEHOLD-2 trial. | Investigational therapy explored for antitumor activity and tolerability in patients with advanced epithelial ovarian, fallopian tube, or peritoneal cancer under Module 2 of the BEHOLD-2 trial. | Guideline-endorsed therapies designed to prolong survival, control disease, and manage symptoms in advanced or relapsed gynecological cancers. |
|---|
| Primary use in this setting | To evaluate antitumor effects and further define the safety profile of Mo-Rez in combination with dostarlimab in women with advanced or recurrent endometrial cancer, after standard options have been exhausted. | To investigate safety, determine an appropriate dose, and explore efficacy of Mo-Rez in combination with or without bevacizumab in women with advanced epithelial ovarian, fallopian tube, or peritoneal cancer, following standard treatment failure or intolerance. | Systemic combination chemotherapy (such as paclitaxel and carboplatin), sometimes with bevacizumab or immunotherapy, is used to control disease, extend survival, and relieve symptoms in advanced or platinum-sensitive relapsed disease. |
|---|
| How it is given or performed | Both Mo-Rez and dostarlimab are administered by intravenous infusion on a schedule set by the trial protocol, in a monitored infusion setting. | Mo-Rez and, when assigned, bevacizumab are both given intravenously. Dosing schedules are per clinical study protocol. | Standard regimens involve intravenous infusion of chemotherapy and/or targeted agents over multiple cycles as per guidelines and established clinical practices. |
|---|
| Evidence status | Efficacy data are not yet established; BEHOLD-2 is a phase 1/2 trial and results are pending. Early clinical data for Mo-Rez in solid tumors are being collected. | Efficacy results from BEHOLD-2 are awaited. Early data are available from related studies but the benefit in this specific ovarian cancer population remains unestablished. | Multiple randomized trials and meta-analyses show survival and disease control benefit for guideline-recommended systemic chemotherapy and targeted therapy in advanced endometrial and ovarian cancers. |
|---|
| Important limitations | Because Mo-Rez is investigational, safety and benefit are not yet fully known. Only selected patients who meet strict eligibility criteria are enrolled, and results may not generalize to all women with advanced endometrial cancer. | Mo-Rez treatment is still under investigation with no established clinical efficacy or long-term safety profile. Outcomes outside trial settings are not yet available. | Not all patients respond to guideline-recommended therapies, and toxicities may limit their use. Treatment decisions often depend on prior exposures, disease biology, and patient preference. |
|---|